Hydatidiform Mole Imaging 

Hydatidiform Mole Imaging 

No Results

No Results


Gestational trophoblastic neoplasia (GTN) represents a spectrum of premalignant and malignant diseases that occur after abnormal fertilization. GTN includes complete hydatidiform mole (CHM), partial hydatidiform mole (PHM), invasive mole, choriocarcinoma, and placental-site trophoblastic tumor (PSTT). CHM and PHM together account for 80% of all cases of GTN. [1, 2, 3, 4, 5]

Hydatidiform moles should be regarded as premalignant lesions because 15-20% of complete hydatidiform moles (CHMs) and 1% of partial hydatidiform moles (PHMs) undergo malignant transformation into invasive moles, choriocarcinomas, or, in rare cases, placental-site trophoblastic tumors (PSTTs). [2, 6]

Ultrasonography is the imaging investigation of choice (see the images below) to confirm the diagnosis of hydatidiform mole. An experienced operator should perform transabdominal and transvaginal imaging using transducers with the highest frequency possible. [7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18] Clinical examination and beta-human chorionic gonadotropin (beta-hCG) determinations are the recommended initial tests for hydatidiform mole.

In some cases, sonographic examination may be limited because of inadequate equipment or inadequate operator experience. The sonographic appearance of a first-trimester hydatidiform mole can be indistinguishable from that of an anembryonic gestation, specifically blighted ovum. Second-trimester complete hydatidiform mole (CHM) can be confused with retained products of conception.

Clinical features of hydatidiform mole in patients 40 years or older may differ from those in younger patients. For example, older patients may have vaginal bleeding, increased uterine volume, and heremesis. [19]

In a multicenter study, many proven cases of hydatidiform mole were not clinically or sonographically evident. Of 155 cases of hydatidiform mole, only 53 (34%) were correctly diagnosed as hydatidiform mole with ultrasonography. [12]  

MRI has no established role in the initial diagnosis of hydatidiform moles. It is useful in malignant forms of gestational trophoblastic neoplasia (GTN) to characterize the degree of myometrial and/or parametrial invasion and to assess the treatment response.

No reliable plain radiographic findings are reported for hydatidiform mole. The associated risks of ionizing radiation disfavor the use of radiography in pregnant women.

No angiographic studies are clinically useful for assessing hydatidiform mole. Performed by an interventional radiologist, selective embolization of the uterine artery is reported as a well-tolerated and effective treatment option for managing severe bleeding from residual uterine vascular malformations in patients with gestational trophoblastic tumors that have been treated. [20, 21]

CT presents a risk of ionizing radiation, and it has no role in the diagnosis of hydatidiform mole. However, if CT is performed, it may show an enlarged uterus with focal areas of hypoattenuation and unilateral or bilateral ovarian enlargement.

In malignant forms of gestational trophoblastic neoplasia (GTN), CT scanning of the head, chest, abdomen, and pelvis are the recommended investigations for detecting metastatic disease.

Hong et al found that, although chest radiography is ineffective in diagnosing pulmonary micrometastases in patients with hydatidiform mole, the use of chest CT should be considered for the initial evaluation of hydatidiform mole. Of 14 patients who underwent chest CT on initial evaluation, 57% were found to have pulmonary micrometastases. [22]

At present, MRI plays no role in the diagnosis of hydatidiform mole.

MRI is indicated in patients with malignant forms of gestational trophoblastic neoplasia (GTN) for an assessment of tumor vascularity and of myometrial and parametrial extension.

MRI findings may include the following [23, 24, 25, 26] :

Heterogeneous endometrial enlargement with several hyperintense foci that represent hydropic villi on T2-weighted imaging

Focal tumor masses in the endometrium and/or myometrium

Loss of uterine zonal anatomy (indistinctness of the endometrial-myometrial border)

Pathologic myometrial, endometrial, and parametrial vasculature characterized by dilated and tortuous vessels

In a series of 13 patients with various histologic types of GTN, Preidler et al found the pathologic uterine vasculature to be the most reliable MRI finding for diagnosing hydatidiform mole. [27] They noted no correlation between the severity of MRI findings and serum beta-hCG levels or specific histologic types of GTN.

Ultrasonography is the imaging investigation of choice for hydatidiform mole. The established roles for sonography include the following [13, 28, 29, 30, 31, 32, 33, 34, 35, 36] :

Initial diagnosis

Assessment of treatment responses

Determination of invasion in malignant forms of gestational trophoblastic neoplasia (GTN)

Determination of recurrent disease in malignant forms of GTN

Ultrasonography should include transabdominal and transvaginal real-time gray-scale imaging by using high-resolution equipment. Early literature described a snowstorm appearance consisting of several echogenic foci, but this finding is no longer seen with new high-resolution ultrasound equipment.

With modern equipment, the typical sonographic appearance of complete hydatidiform mole (CHM) in the second and third trimesters is an enlarged uterine endometrial cavity containing innumerable anechoic cysts sized 1-30 mm (see the images below). On pathologic examination, these cysts represent grossly swollen (hydropic) chorionic villi that have a bunch-of-grapes appearance. [17]

In the first trimester, the sonographic appearance of CHM is relatively nonspecific. The classic finding of multiple, tiny, anechoic cystic spaces is rarely seen. The most common sonographic appearance of CHM in the first trimester is a homogeneously hyperechoic endometrial mass. An anembryonic gestation (empty gestational sac) may be the only sonographic finding (see images below); if it is, its distinction from blighted ovum is difficult or impossible.

Sonograms of partial hydatidiform mole (PHM) may show cystic changes similar to those of CHM but in a more focal distribution. The major distinguishing feature of PHM is embryonic tissue (see the image below). In practice, PHM can be difficult to distinguish from CHM on sonograms, and this distinction is usually made pathologically. This limitation is insignificant because the management approaches are similar for CHM and for PHM.

Theca lutein ovarian cysts are present in 50% of hydatidiform moles. They result from ovarian hyperstimulation secondary to high circulating levels of beta-human chorionic gonadotropin (hCG). On sonograms, theca lutein cysts appear as large, septate cystic ovarian lesions. They may be unilateral or bilateral, and they may be extremely large. If the lesions are large, transabdominal scanning is needed to completely visualize them. The presence of bilateral and/or large theca luteins is well correlated with serum beta-hCG levels >100,000 mIU/mL.

Theca lutein cysts usually resolve within 8-12 weeks after hydatidiform moles are evacuated. [37] Cysts that persist after beta-hCG levels return to normal should prompt further workup to exclude a neoplastic process. In rare cases, theca lutein cysts rupture, hemorrhage, or cause ovarian torsion.

When theca lutein cysts are present, the radiologist must recommend appropriate imaging follow-up to exclude the small possibility of a preexisting or concomitant cystic ovarian neoplasm. This follow-up should include sonographic evaluation after serum beta-hCG levels are normalized. In most patients, theca lutein cysts regress within 8-12 weeks after the hydatidiform mole is evacuated.

Doppler ultrasonography has no clearly defined role in the evaluation of hydatidiform mole. However, it is useful in diagnosing invasive forms of GTN, in which cystic vascular spaces with high-velocity, low-impedance flow are almost always demonstrated. Doppler ultrasonography also plays a role in monitoring the response of the disease after chemotherapy. Regression of cystic vascular masses is observed after successful treatment. [13, 36, 38, 16]

According to Kerkmeijer et al, earlier serum hCG regression in patients with complete hydatidiform moles is likely the result of first-trimester ultrasonography that leads to detection and evacuation of complete moles at younger gestational ages, thereby resulting in lower hCG levels at the time of evacuation. The investigators found that 99% of a recent cohort achieved hCG normalization within 19 weeks after uterine evacuation as compared with 25 weeks in a historic group. [14]

Sebire et al reviewed findings in 155 women in histologically proven complete hydatidiform moles (CHMs) or partial hydatidiform moles (PHMs) who had previous sonograms. [12] In only 34% was a molar pregnancy diagnosed. In the remainder, the condition was misdiagnosed as a miscarriage. [39] Accuracy was higher with CHMs (37 [58%] of 64 patients) than with PHMs (16 [18%] of 91 patients).

In a single-center study of first-trimester CHM, initial sonographic diagnoses were made in 17 (71%) of 24 cases. [15] Early pregnancy failure was the most common alternative diagnosis in the cases that were missed.

In a Swedish study, ultrasound predicted a molar diagnosis in 73% of cases of CHM but only 35% of cases of PHM. [40]

The radiologist must recognize that a first-trimester hydatidiform mole can be pathologically and sonographically indistinguishable from an early pregnancy failure [3]  . Sonograms may simply show an empty gestational sac without other findings to suggest a hydatidiform mole. In a single-center study of first-trimester CHM, an initial sonographic diagnosis was made in 17 (71%) of 24 cases. [15] Early pregnancy failure was the most common alternative diagnosis in the cases that were missed.

The radiologist must maintain a high index of suspicion for hydatidiform mole in the first trimester, even when it is not suspected based on clinical findings. The serum beta-hCG level may be normal, and clinical findings may be absent or minimal. The classic clinical findings of vaginal bleeding, anemia, hyperemesis gravidarum, preeclampsia, and hyperthyroidism are usually absent until the second trimester.

No nuclear medicine studies are clinically useful for evaluating hydatidiform mole. Positron emission tomography (PET) and PET CT show promise as problem-solving tools in malignant forms of gestational trophoblastic neoplasia (GTN). Selected case reports and case series demonstrated the usefulness of PET for identifying lesions in patients with GTN and with negative or equivocal ultrasonographic, CT, and MRI findings. [41, 42]

Data about the effectiveness of PET in evaluating GTN are limited. Grisaru et al reported that PET CT had a sensitivity of 97% and a specificity of 94% for gynecologic malignancy. [41] However, of their 53 patients, only 1 had GTN. The rest had various other types of cancer, including ovarian, uterine, vaginal and cervical.

Green CL, Angtuaco TL, Shah HR, Parmley TH. Gestational trophoblastic disease: a spectrum of radiologic diagnosis. Radiographics. 1996 Nov. 16(6):1371-84.

Hurteau JA. Gestational trophoblastic disease: management of hydatidiform mole. Clin Obstet Gynecol. 2003. 46:557-69. [Medline].

Lima LL, Parente RC, Maestá I, Amim Junior J, de Rezende Filho JF, Montenegro CA, et al. Clinical and radiological correlations in patients with gestational trophoblastic disease. Radiol Bras. 2016 Jul-Aug. 49 (4):241-250. [Medline]. [Full Text].

Bruce S, Sorosky J. Gestational Trophoblastic Disease. STATPearls. 2018 Jan. [Medline]. [Full Text].

Ghassemzadeh S, Kang M. Hydatidiform Mole. StatPearls. 2018 Jan. [Medline]. [Full Text].

Sebire NJ, Makrydimas G, Agnantis NJ, et al. Updated diagnostic criteria for partial and complete hydatidiform moles in early pregnancy. Anticancer Res. 2003 Mar-Apr. 23(2C):1723-8.

Allen SD, Lim AK, Seckl MJ, et al. Radiology of gestational trophoblastic neoplasia. Clin Radiol. 2006 Apr. 61(4):301-13.

DeBaz BP, Lewis TJ. Imaging of gestational trophoblastic disease. Semin Oncol. 1995 Apr. 22(2):130-41. [Medline].

Dipi RM, Amin MS, Islam MN, Khan NA, Chaiti MM, Hossain MM. Comparison of transabdominal and transvaginal sonography in the evaluation of uterine mass with histopathological correlation. Mymensingh Med J. 2013 Jan. 22(1):69-74. [Medline].

Unsal MA, Guven S. Complete hydatidiform mole coexisting with a live fetus. Clin Exp Obstet Gynecol. 2012. 39(2):262-4. [Medline].

Sasaki Y, Ogawa K, Takahashi J, Okai T. Complete hydatidiform mole coexisting with a normal fetus delivered at 33 weeks of gestation and involving maternal lung metastasis: a case report. J Reprod Med. 2012 Jul-Aug. 57(7-8):301-4. [Medline].

Sebire NJ, Rees H, Paradinas F, et al. The diagnostic implications of routine ultrasound examination in histologically confirmed early molar pregnancies. Ultrasound Obstet Gynecol. 2001 Dec. 18(6):662-5.

Zhou Q, Lei XY, Xie Q, Cardoza JD. Sonographic and Doppler imaging in the diagnosis and treatment of gestational trophoblastic disease: a 12-year experience. J Ultrasound Med. 2005 Jan. 24(1):15-24.

Kerkmeijer LG, Massuger LF, Ten Kate-Booij MJ, Sweep FC, Thomas CM. Earlier diagnosis and serum human chorionic gonadotropin regression in complete hydatidiform moles. Obstet Gynecol. 2009 Feb. 113(2 Pt 1):326-31. [Medline].

Benson CB, Genest DR, Bernstein MR, et al. Sonographic appearance of first trimester complete hydatidiform moles. Ultrasound Obstet Gynecol. 2000 Aug. 16(2):188-91.

Asmar FTC, Braga-Neto AR, de Rezende-Filho J, Villas-Boas JMS, Charry RC, Maesta I. Uterine artery Doppler flow velocimetry parameters for predicting gestational trophoblastic neoplasia after complete hydatidiform mole, a prospective cohort study. Clinics (Sao Paulo). 2017 May. 72 (5):284-288. [Medline].

Fonseca EKUN, Rodrigues MAS, Yamauchi FI, Baroni RH. “Bunch of grapes” in complete hydatidiform mole. Abdom Radiol (NY). 2017 May. 42 (5):1606-1607. [Medline].

Gupta K, Venkatesan B, Kumaresan M, Chandra T. Early Detection by Ultrasound of Partial Hydatidiform Mole With a Coexistent Live Fetus. WMJ. 2015 Oct. 114 (5):208-11; quiz 212. [Medline].

Mangili G, Giorgione V, Gentile C, Bergamini A, Pella F, Almirante G, et al. Hydatidiform mole: age-related clinical presentation and high rate of severe complications in older women. Acta Obstet Gynecol Scand. 2014 May. 93 (5):503-7. [Medline].

Lim AK, Agarwal R, Seckl MJ, et al. Embolization of bleeding residual uterine vascular malformations in patients with treated gestational trophoblastic tumors. Radiology. 2002 Mar. 222(3):640-4.

Vogelzang RL, Nemcek AA, Skrtic Z, et al. Uterine arteriovenous malformations: primary treatment with therapeutic embolization. J Vasc Interv Radiol. 1991 Nov. 2(4):517-22. [Medline].

Hong DG, Cho YL, Park IS, Lee YS. Chest computed tomography before evacuation of hydatidiform mole. Eur J Gynaecol Oncol. 2009. 30(2):151-4. [Medline].

Barton JW, McCarthy SM, Kohorn EI, et al. Pelvic MR imaging findings in gestational trophoblastic disease, incomplete abortion, and ectopic pregnancy: are they specific?. Radiology. 1993 Jan. 186(1):163-8.

Hricak H, Demas BE, Braga CA, et al. Gestational trophoblastic neoplasm of the uterus: MR assessment. Radiology. 1986 Oct. 161(1):11-6.

Imaoka I, Sugimura K, Masui T, et al. Abnormal uterine cavity: differential diagnosis with MR imaging. Magn Reson Imaging. 1999 Dec. 17(10):1445-55.

Powell MC, Buckley J, Worthington BS, Symonds EM. Magnetic resonance imaging and hydatidiform mole. Br J Radiol. 1986 Jun. 59(702):561-4.

Preidler KW, Luschin G, Tamussino K, et al. Magnetic resonance imaging in patients with gestational trophoblastic disease. Invest Radiol. 1996 Aug. 31(8):492-6.

Müngen E, Dundar O, Muhcu M, Haholu A, Tunca Y. Placental mesenchymal dysplasia associated with trisomy 13: sonographic findings. J Clin Ultrasound. 2008 Sep. 36(7):454-6. [Medline].

Dighe M, Cuevas C, Moshiri M, Dubinsky T, Dogra VS. Sonography in first trimester bleeding. J Clin Ultrasound. 2008 Jul-Aug. 36(6):352-66. [Medline].

Raga F, Bonilla F, Sanz-Cortés M, Bonilla-Musoles F. Three-dimensional inversion mode rendering in molar pregnancy. Ultrasound Obstet Gynecol. 2008 Mar. 31(3):362-3. [Medline].

Goldstein SR. Early detection of pathologic pregnancy by transvaginal sonography. J Clin Ultrasound. 1990. 18(4):262-73.

Kohorn EI, McCarthy SM, Taylor KJ. Nonmetastatic gestational trophoblastic neoplasia. Role of ultrasonography andmagnetic resonance imaging. J Reprod Med. 1998. 43:14-20.

Naumoff P, Szulman AE, Weinstein B, et al. Ultrasonography of partial hydatidiform mole. Radiology. 1981 Aug. 140(2):467-70.

Reid MH, McGahan JP, Oi R. Sonographic evaluation of hydatidiform mole and its look-alikes. AJR Am J Roentgenol. 1983. 140(2):307-11.

Sauerbrei E, Khan N, Nolan R. A Practical Guide to Ultrasound in Obstetrics and Gynecology, 2nd ed. Philadelphia, Pa: Lippincott Williams & Wilkins;. 1998.

Taylor KJ, Schwartz PE, Kohorn EI. Gestational trophoblastic neoplasia: diagnosis with Doppler US. Radiology. 1987. 165(2):445-8.

Montz FJ, Schlaerth JB, Morrow CP. The natural history of theca lutein cysts. Obstet Gynecol. 1988. 72(2):247-51.

Carter J, Fowler J, Carlson J, et al. Transvaginal color flow Doppler sonography in the assessment of gestational trophoblastic disease. J Ultrasound Med. 1993 Oct. 12(10):595-9.

Krishnamoorthy K, Gerkowicz S, Verma U. Viable Intrauterine Pregnancy and Coexisting Molar Pregnancy in a Bicornuate Uterus: A Rare Presentation. J Clin Imaging Sci. 2016. 6:26. [Medline]. [Full Text].

Joneborg U, Marions L. Current clinical features of complete and partial hydatidiform mole in Sweden. J Reprod Med. 2014 Jan-Feb. 59 (1-2):51-5. [Medline].

Grisaru D, Almog B, Levine C, et al. The diagnostic accuracy of 18F-fluorodeoxyglucose PET/CT in patients with gynecological malignancies. Gynecol Oncol. 2004 Sep. 94(3):680-4.

Sironi S, Picchio M, Mangili G, et al. [18F]fluorodeoxyglucose positron emission tomography as a useful indicator of metastatic gestational trophoblastic tumor: preliminary results in three patients. Gynecol Oncol. 2003 Oct. 91(1):226-30.

Daniel D Mott, MD, FRCPC Fellow in Neuroradiology, Yale-New Haven Hospital and Yale-New Haven Children’s Hospital

Daniel D Mott, MD, FRCPC is a member of the following medical societies: American Roentgen Ray Society, Canadian Medical Association, College of Physicians and Surgeons of Ontario, Ontario Medical Association, Radiological Society of North America, Royal College of Physicians and Surgeons of Canada, Canadian Medical Protective Association, Canadian Association of Radiologists

Disclosure: Nothing to disclose.

Eric E Sauerbrei, MD Professor of Radiology and Obstetrics and Gynecology, Director of Resident’s Radiology Research, Department of Radiology, Queen’s University; Director of Ultrasound, Kingston General Hospital, Hotel Dieu Hospital

Eric E Sauerbrei, MD is a member of the following medical societies: American Institute of Ultrasound in Medicine, Canadian Medical Association, Ontario Medical Association, Radiological Society of North America

Disclosure: Nothing to disclose.

Karen L Reuter, MD, FACR Professor, Department of Radiology, Lahey Clinic Medical Center

Karen L Reuter, MD, FACR is a member of the following medical societies: American Association for Women Radiologists, American College of Radiology, American Institute of Ultrasound in Medicine, American Roentgen Ray Society, Radiological Society of North America

Disclosure: Nothing to disclose.

Eugene C Lin, MD Attending Radiologist, Teaching Coordinator for Cardiac Imaging, Radiology Residency Program, Virginia Mason Medical Center; Clinical Assistant Professor of Radiology, University of Washington School of Medicine

Eugene C Lin, MD is a member of the following medical societies: American College of Nuclear Medicine, American College of Radiology, Radiological Society of North America, Society of Nuclear Medicine and Molecular Imaging

Disclosure: Nothing to disclose.

Hydatidiform Mole Imaging 

Research & References of Hydatidiform Mole Imaging |A&C Accounting And Tax Services